MediciNova collaborates on ibudilast

17 January 2012

California, USA-based Japanese bio-venture company MediciNova (Nasdaq: MNOV and TYO: 4875) and the University of Colorado (CU) Boulder disclosed a license agreement for the use of ibudilast (MN-166/AV411) for the treatment of post-traumatic brain injury (TBI). Financial terms of the accord were not disclosed.

Research led by Daniel Barth, Professor of Neuroscience and Psychology at CU-Boulder, ibudilast demonstrated significant efficacy in a model of post-TBI anxiety, one of the most common disorders caused by TBI. Dr Barth and colleague, Krista Rodgers, discovered that a short course of systemic ibudilast administered over a month after concussion injury reversed post-TBI anxiety in rats for a three-month measurement period following treatment.

Surprising efficacy findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK